entrance between 20th and 21st Streets, NW., Washington, DC 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION:

Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204. You may call (202) 452–3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: March 13, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board. [FR Doc. 96–6384 Filed 3–13–96; 11:02 am] BILLING CODE 6210–1–P

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 10:00 a.m., Wednesday, March 20, 1996.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, NW., Washington, DC 20551.

STATUS: Open.

MATTERS TO BE CONSIDERED:

1. Proposed amendments to simplify, clarify, and update Regulation E (Electronic Fund Transfers) (proposed earlier for public comment; Docket No. R–0830).

2. Publication for comment of proposed amendments to Regulation E (Electronic Fund Transfers) concerning stored-value cards, electronic communications, and error resolution.

3. Any items carried forward from a previously announced meeting.

Note: This meeting will be recorded for the benefit of those unable to attend. Cassettes will be available for listening in the Board's Freedom of Information Office, and copies may be ordered for \$5 per cassette by calling (202) 452–3684 or by writing to:

Freedom of Information Office, Board of Governors of the Federal Reserve System, Washington, DC 20551.

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204.

Dated: March 13, 1996. Jennifer J. Johnson, *Deputy Secretary of the Board.* [FR Doc. 96–6385 Filed 3–13–96; 11:02 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Agency Information Collection Activities: Proposed Collections; Comment Request

The Department of Health and Human Services, Office of the Secretary will periodically publish summaries of proposed information collections projects and solicit public comments in compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995. To request more information on the project or to obtain a copy of the information collection plans and instruments, call the OS Reports Clearance Officer on (202) 619– 1053.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility: (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

1. JOBS Evaluation: Five Year Followup—New—As a part of the on-going JOBS program evaluation, the Office of the Assistant Secretary for Planning and Evaluation is planning a Five-year Recipient Survey and a Child School Progress Survey. This information will be combined with other data sources in the process of evaluating the JOBS program.-Respondents: individuals or households-Burden Information for Recipient Survey—Respondents: 4,500; Average Burden per Response: 1 hour; Total Burden for Recipient Survey: 4,500 hours-Burden Information for Child School Progress Survey-Respondents: 2,225; Average Burden per Response: 15 minutes; Total Burden for Child School Progress Survey: 563 hours-Total Burden: 5.063 hours.

Send comments to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 530H, Humphrey Building, 200 Independence Avenue, S.W., Washington, DC, 20201. Written comments should be received within 60 days of this notice. Dated: March 7, 1996. Dennis P. Williams, Deputy Assistant Secretary, Budget. [FR Doc. 96–6168 Filed 3–14–96; 8:45 am] BILLING CODE 4150–04–M

Agency for Toxic Substances and Disease Registry

Board of Scientific Counselors, Agency for Toxic Substances and Disease Registry; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Agency for Toxic Substances and Disease Registry (ATSDR) announces the following committee meeting.

Name: Board of Scientific Counselors, Agency for Toxic Substances and Disease Registry (BSC, ATSDR). Times and Dates:

Times and Dates

1 p.m.-5 p.m., April 16, 1996.

8 a.m.–3:15 p.m., April 17, 1996. *Place:* The Agency for Toxic Substances and Disease Registry, Training Room, Building 35, 35 Executive Park Drive, NE, Atlanta, Georgia 30329.

Status: Open to the public, limited only by the space available.

Purpose: The Board of Scientific Counselors, ATSDR, advises the Administrator, ATSDR, on ATSDR programs to ensure scientific quality, timeliness, utility, and dissemination of results. Specifically, the Board advises on the adequacy of the science in ATSDR-supported research, emerging problems that require scientific investigation, accuracy and currency of the science in ATSDR reports, and program areas to emphasize and/or to deemphasize.

Matters To Be Discussed: Agenda items will include an update on Superfund reauthorization and will also focus on other issues of concern to ATSDR, including the ATSDR Minority Health and Environmental Justice Program, Mississippi Delta Project (Health and Environment), Assessing Demographic Parameters at National Priorities List (NPL) Sites, Howard **Emergency Medicine Rotation Program**, Hispanic Internship Program, Tribal Cooperative Agreement Program, Head Start Environmental Health Program, Risk Communication Project (Sheboygan Harbor and River), Enhancing Community Involvement (ATSDR Cooperative Agreements), Work Group on Health Studies Update, ATSDR's Children's Health Initiative, Laboratory Methods to Measure Contaminants in Biological Media, and Significant Human Exposure Levels Update.

Written comments are welcome and should be received by the contact person listed below prior to the opening of the meeting.

FOR FURTHER INFORMATION CONTACT: Charles Xintaras, Sc.D., Executive Secretary, BSC, ATSDR, M/S E–28, 1600 Clifton Road, NE, Atlanta, Georgia 30333, telephone 404/639–0708.

Dated: March 11, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC). [FR Doc. 96–6191 Filed 3–14–96; 8:45 am] BILLING CODE 4163–70–M

Food and Drug Administration

[Docket No. 96N-0075]

Hance Brothers and White Co., et al.; Proposal to Withdraw Approval of 17 Abbreviated Applications; Opportunity for a Hearing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for a hearing on the agency's proposal to withdraw approval of 3 abbreviated antibiotic applications (AADA's) and 14 abbreviated new drug applications (ANDA's). The basis for the proposal is that the sponsors have repeatedly failed to file required annual reports for these applications.

DATES: Written requests for a hearing are due by April 15, 1996; data and information in support of the hearing request are due by May 14, 1996.

ADDRESSES: Requests for a hearing, supporting data, and other comments should be identified with Docket No. 96N–0075 and submitted to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1038.

SUPPLEMENTARY INFORMATION: The holders of approved applications to market new drugs or antibiotic drugs for human use are required to submit annual reports to FDA concerning each of their approved applications in accordance with § 314.81 (21 CFR 314.81). The holders of the AADA's and ANDA's listed in the table below have failed to submit the required annual reports, and have not responded to the agency's requests by certified mail for submission of the reports.

Application no.	Drug	Applicant
AADA	Neomycin and Polymyxin	Hance Brothers and White Co.
60–276	B Sulfates and Bacitracin Ointment	
AADA	Tetracycline	Premo Pharmaceutica Laboratories, Inc.
60–422	Hydrochloride Tablets	
AADA	Erythromycin Estolate	Life Laboratories, Inc.
62–362	Suspension, 250	
	Milligrams (mg) per 5	
	Milliliters (mL)	
ANDA	Isoniazid Tablets, 300 mg	Everylife.
80–126		
	Cyanocobalamin Injection	Dell Laboratories, Inc.
689	USP, 30 micrograms	
	(μg) per mL, 100 μg/mL,	
and 100 μg/mL		
ANDA	Lidocaine Hydrochloride	Do.
33–387	Injection USP, 1%	20.
ANDA	Lidocaine Hydrochloride	Do.
33–388	Injection USP, 2%	20.
ANDA	Vitamin A Capsules USP	Wharton Laboratories.
33–665		Whatton Eaboratories.
ANDA	Pyridoxine Hydrochloride	Dell Laboratories, Inc.
33–771	Injection USP, 50	
ю <i>-тт</i> т	mg/mL	
ANDA	Pyridoxine Hydrochloride	Do.
3–772	Injection USP, 100 mg/mL	D0.
NDA	Thiamine Hydrochloride	Do.
3–775	Injection USP, 100 mg/mL	D0.
ANDA	Chlorpheniramine Maleate	Newtron Pharmaceuticals, Inc
36–519	Tablets, USP, 4 mg	
NDA	Brompheniramine Maleate	Do.
36–987		D0.
	Tablets, USP, 4 mg	Marahar Laboratorian Ltd
NDA 17–791	Fluorouracil Injection,	Marcher Laboratories, Ltd.
	50 mg/mL	Above Dhermonoutingle las
NDA	Hydrocodone Bitartrate	Abana Pharmaceuticals, Inc.
38–871	and Acetaminophen,	
	5 mg/500mg	
ANDA	Acetaminophen and Codeine	Superpharm Corp.
39–184	Phosphate Tablets, USP, 300 mg/30 mg	K. M. Las Laboratorias
ANDA	Meprobamate Tablets, USP, 400 mg	K. M. Lee Laboratories
39–538		

Therefore, notice is given to the holders of the AADA's and ANDA's listed in the table and to all other interested persons that the Director of the Center for Drug Evaluation and Research proposes to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(e)) withdrawing approval of the AADA's and ANDA's and all amendments and supplements thereto on the ground that the applicants have